title: Delirium secondary to intrathecal baclofen.
abstract: METHODS
  Retrospective study based on a revision of the clinical histories of all patients carrying an intrathecal baclofen (ITB) infusion system between July 1988 and March 2007 in a neurorehabilitation hospital.
  
  
  OBJECTIVE
  To describe the psychiatric manifestations due to intoxication or withdrawal of ITB and to explore the possible risk factors for the presentation of delirium secondary to baclofen.
  
  
  METHODS
  Spinal Cord Injury Unit in Barcelona, Spain.
  
  
  METHODS
  We selected patients who presented delirium related to baclofen treatment. We filtered these cases by the search of key words. All the compatible episodes were then reviewed and positive cases were confirmed to perform a descriptive analysis of the different variables. Control subjects were randomly selected for a comparative analysis of the aspects of interest.
  
  
  RESULTS
  A total of 12 of the 126 patients carrying the intrathecal system in our hospital presented delirium related to baclofen. Eight cases due to intoxication (66.6%) and four due to withdrawal (33.3%) were found. We provide a description of the psychiatric symptoms. There were no fatal cases due to delirium.
  
  
  CONCLUSIONS
  Delirium has a frequency of 9.5% in patients carrying the ITB infusion system, intoxication being more frequent than withdrawal.
authors.affiliation: Institut Guttmann, Neurorehabilitation Hospital, Spinal Cord Injury Unit, Badalona, Spain. bcastano@guttmann.com
authors.forename: B
authors.initials: B
authors.lastname: Castaño
authors.forename: J
authors.initials: J
authors.lastname: Benito
authors.forename: F
authors.initials: F
authors.lastname: Pires
authors.forename: S
authors.initials: S
authors.lastname: Ferreira
authors.forename: R
authors.initials: R
authors.lastname: Lopez
authors.forename: J
authors.initials: J
authors.lastname: Vidal
mesh_terms: D000328:Adult; D001418:Baclofen / Q000009:adverse effects*; D003693:Delirium / Q000139:chemically induced*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007278:Injections, Spinal / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009125:Muscle Relaxants, Central / Q000009:adverse effects*; D012189:Retrospective Studies; D013375:Substance Withdrawal Syndrome / Q000503:physiopathology*
chemical_list: D009125:Muscle Relaxants, Central; D001418:Baclofen